Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
Amgen Astellas Biopharma K.K., a joint venture of Astellas Pharma and US-based Amgen, filed a new drug application in Japan on March 20 for evolocumab (development code: AMG145), an anti-PCSK9 monoclonal antibody for the treatment of hypercholesterolemia. Originated by Amgen,…
To read the full story
Related Article
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
BUSINESS
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
- Teijin, ASKA Hook Up on Gynecology Drug Discovery
February 18, 2026
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…